Warrant Agreement



 Exhibit 4.1 
 Execution Copy 
 THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES WHICH MAY BE ISSUED
UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES OR BLUE SKY LAWS. NO SALE OR DISTRIBUTION HEREOF OR THEREOF MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED
THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER APPLICABLE SECURITIES LAWS. 
 WARRANT AGREEMENT 
 THIS WARRANT AGREEMENT (this
“Agreement”) is dated this 6th day of January
2012, by and between NeoGenomics, Inc., a Nevada corporation (the “Company”), and Maher Albitar, M.D., an individual residing at 27165 Kiavo Drive, Valley Center, CA 92082 (the “Warrant Holder”). 

W I T N E S S E T H 

WHEREAS, as of the date hereof, the Company has entered into a Letter Agreement and a Medical Services Agreement with the Warrant Holder
pursuant to which the Warrant Holder has been retained as the Chief Medical Officer of the Company; and 
 WHEREAS, in addition
to entering into the Letter Agreement and the Medical Services Agreement with the Warrant Holder, the Company desires to provide an additional incentive for the Warrant Holder to create shareholder value for the Company’s shareholders and has
agreed to issue to the Warrant Holder a warrant (the “Warrant”) to purchase an aggregate of 200,000 shares of the Company’s common stock, par value $0.001/share (“Common Stock”). 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and promises contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1.
Incorporation of Recitals. The Recitals portion of this Agreement is hereby incorporated by this reference as though it were fully set forth and rewritten herein, and the affirmative statements therein contained shall be deemed to be
representations of the Company and the Warrant Holder, which are hereby confirmed. 
 2. Warrant. The Company hereby
grants to the Warrant Holder, subject to the terms set forth herein, the right to purchase, subject to the vesting schedule set forth in Section 12 hereof, at any time during the term (the “Warrant Exercise Term”) commencing on the
date hereof and ending at 5:30 p.m., New York time on the fifth anniversary of the date of this Agreement (the “Expiration Date”) 200,000 shares of Common Stock (the “Shares”), at an exercise price of $1.43 per share (the
“Exercise Price”). 
 3. Exercise of Warrant. 

3.1 Exercise. The Warrant may be exercised by the Warrant Holder, in whole or in part, by delivering the Notice of Exercise
purchase form, attached as Exhibit A hereto (the 







 
“Notice of Exercise”), duly executed by the Warrant Holder to the Company at its principal office, or at such other office as the Company may designate, accompanied by payment, in cash
or by wire transfer or check payable to the order of the Company, of the amount obtained by multiplying the number of Shares designated in the Notice of Exercise by the Exercise Price (the “Purchase Price”). The Purchase Price may also be
paid, in whole or in part, by delivery of such purchase form and of shares of Common Stock owned by the Warrant Holder having a Market Price (as defined in Section 3.3 hereof) on the last business day ending the day immediately prior to the
Exercise Date (as defined below) equal to the portion of the aggregate Exercise Price being paid in such shares. In addition, the Warrant may be exercised, pursuant to a cashless exercise by providing irrevocable instructions to the Company, through
delivery of the Notice of Exercise with an appropriate reference to this Section 3.1 to issue the number of shares of the Common Stock equal to the product of (a) the number of shares as to which the Warrant is being exercised multiplied
by (b) a fraction, the numerator of which is the Market Price of a share of the Common Stock on the last business day preceding the Exercise Date less the Exercise Price therefor and the denominator of which is such Market Price. For purposes
hereof, “Exercise Date” shall mean the date on which all deliveries required to be made to the Company upon exercise of the Warrant pursuant to this Section 3.1 shall have been made. 

3.2 Issuance of Certificates. As soon as practicable after the exercise of the Warrant (in whole or in part) in accordance with
Section 3.1 hereof, the Company, at its expense, shall cause to be issued in the name of and delivered to the Warrant Holder (i) a certificate or certificates for the number of fully-paid and non-assessable Shares to which the Warrant
Holder shall be entitled upon such exercise and (if applicable) (ii) a new warrant agreement of like tenor to purchase all of the Shares that may be purchased pursuant to the portion, if any, of the Warrant not exercised by the Warrant Holder.
The Warrant Holder shall for all purposes be deemed to have become the holder of record of such Shares on the date on which the Notice of Exercise and payment of the Purchase Price in accordance with Section 3.1 hereof were delivered and made,
respectively, irrespective of the date of delivery of such certificate or certificates, except that if the date of such delivery, notice and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to
have become the holder of record of such Shares at the close of business on the next succeeding date on which the stock transfer books are open. 
 3.3 Market Price. The “Market Price” of a share of Common Stock means: the average of the daily closing price of shares of Common Stock on the principal market on which shares of the
Common Stock are traded for the five (5) trading days immediately preceding the date of the determination of the Market Price. If shares of Common Stock are not traded on any public market (e.g. NYSE, AMEX, NASDAQ, OTCBB or Pink Sheets), the
Market Price of the Common Stock shall be determined, in good faith, by the Board of Directors of the Company (the “Board”). 
 4. Adjustments. 
 4.1 Stock Splits, Stock Dividends and
Combinations. If the Company at any time subdivides the outstanding shares of the Common Stock or issues a stock dividend (in Common Stock) on the outstanding shares of the Common Stock, the Exercise Price in effect immediately prior to such
subdivision or the issuance of such stock dividend shall be 

  
 2 








 
proportionately decreased, and the number of Shares subject hereto shall be proportionately increased, and if the Company at any time combines (by reverse stock split or otherwise) the
outstanding shares of Common Stock, the Exercise Price in effect immediately prior to such combination shall be proportionately increased, and the number of Shares subject hereto shall be proportionately decreased, effective at the close of business
on the date of such subdivision, stock dividend or combination, as the case may be. 
 4.2 Merger or Consolidation. In
the case of any consolidation of the Company with, or merger of the Company with or into another entity (other than a consolidation or merger which does not result in any reclassification or change of the outstanding capital stock of the Company),
the entity formed by such consolidation or merger shall execute and deliver to the Warrant Holder a supplemental warrant agreement providing that the Warrant Holder of the Warrant then outstanding or to be outstanding shall have the right thereafter
(until the expiration of such Warrant) to receive, upon exercise of such Warrant, the kind and amount of shares of capital stock and other securities and property receivable upon such consolidation or merger by a holder of the number of Shares for
which such Warrant might have been exercised immediately prior to such consolidation or merger. Such supplemental warrant agreement shall provide for adjustments which shall be identical to the adjustments provided in Section 4.1 hereof and to
the provisions of Section 11 hereof. This Section 4.2 shall similarly apply to successive consolidations or mergers. 

5. Transfers. 
 5.1 Unregistered Securities. Warrant Holder hereby acknowledges and agrees that the Warrant and the Shares have not been registered under the Securities Act of 1933, as amended (the
“Securities Act”), and are “restricted securities” under the Securities Act inasmuch as they are being acquired in a transaction not involving a public offering, and the Warrant Holder agrees not to sell, pledge, distribute,
offer for sale, transfer or otherwise dispose of the Warrant or any Shares issued upon exercise of the Warrant in the absence of (a) an effective registration statement under the Securities Act as to the Warrant or such Shares and registration
and/or qualification of the Warrant or such Shares under any applicable Federal or state securities law then in effect or (b) an opinion of counsel, reasonably satisfactory to the Company, that such registration and qualification are not
required. 
 5.2 Transferability. Until such time as the Shares are vested pursuant to Section 12 hereof, the rights
under this Agreement with respect to such Shares shall not be transferrable. After all or any portion of the Shares have vested pursuant to Section 12 hereof, then subject to the provisions of Section 5.1 hereof, the rights under this
Agreement relating only to that portion of the Shares that are vested are freely transferable, in whole or in part, by the Warrant Holder, and such transferee shall have the same rights hereunder as the Warrant Holder. 

5.3 Warrant Register. The Company will maintain a register containing the names and addresses of the Warrant Holders of the
Warrant. Until any transfer of Warrant in accordance with this Agreement is reflected in the warrant register, the Company may treat the Warrant Holder as the absolute owner hereof for all purposes. Any Warrant Holder may change such Warrant
Holder’s address as shown on the warrant register by written notice to the Company requesting such change. 

  
 3 








 6. No Fractional Shares. Any adjustment in the number of Shares purchasable hereunder
shall be rounded to the nearest whole share. 
 7. Investment Representations. The Warrant Holder agrees and acknowledges
that it is acquiring the Warrant and will be acquiring the Shares for his own account and not with a view to any resale or distribution other than in accordance with Federal and state securities laws. The Warrant Holder is an “accredited
investor” within the meaning of Rule 501(a) of Regulation D promulgated under the Securities Act. 
 8. Covenants as to
the Shares. The Company covenants and agrees that the shares of Common Stock issuable upon exercise of the Warrant, will, upon issuance in accordance with the terms hereof, be duly and validly issued and outstanding, fully-paid and
non-assessable, with no personal liability attaching to the ownership thereof. The Company further covenants and agrees that the Company will at all times have authorized and reserved a sufficient number of shares of Common Stock to provide for the
exercise of the rights represented under this Agreement. The Company will pay all documentary stamp taxes attributable to the initial issuance of Shares upon the exercise of the Warrant; provided, however, that the Company shall not be
required to pay any tax or taxes which may be payable in respect of any transfer involved in the issue of any certificates for Shares in a name other than that of the Warrant Holder, and the Company shall not be required to issue or deliver such
certificates unless or until the person or persons requesting the issuance thereof shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax has been paid. 

9. Legend. Any certificate evidencing the Shares issuable upon exercise hereof will bear a legend indicating that such securities
have not been registered under the Securities Act or under any state securities laws and may not be sold or offered for sale in the absence of an effective registration statement as to the securities under the Securities Act and any applicable state
securities law or an opinion of counsel reasonably satisfactory to the Company that such registration is not required. 
 10.
Rights Applicable to the Warrant Shares. The parties hereby acknowledge and agree that the Shares, when issued in accordance with the terms hereof, shall be entitled to all of the same rights and privileges provided to the Company’s
Common Stock. 
 11. Dividends and Other Distributions. In the event that the Company shall, at any time prior to the
exercise of all Warrants, declare a dividend (other than a dividend consisting solely of shares of Common Stock) or otherwise distribute to its stockholders any assets, properties, rights, evidence of indebtedness, securities (other than shares of
Common Stock), whether issued by the Company or by another, or any other thing of value, the Warrant Holder shall thereafter be entitled, in addition to the shares of Common Stock or other securities and property receivable upon the exercise
thereof, to receive, upon the exercise of such Warrant, the same assets, property, rights, evidences of indebtedness, securities or any other thing of value that the Warrant Holder would have been entitled to receive at the time of such dividend or
distribution as if the Warrant had been exercised immediately prior to such dividend or distribution. At the time of any such dividend or distribution, the Company shall make (and maintain) appropriate reserves to ensure the timely performance of
the provisions of this Section 11. 

  
 4 








 12. Vesting. The Warrant shall only be exercisable in whole or in part, according to
the following vesting schedule: 
 80,000 of the Shares will vest upon the commercial launch of the Company’s gene/gene
product-based plasma prostate cancer test licensed from Health Discovery Corporation (“HDC”) or similar test based on mutual written agreement with the Company. 
 40,000 of the Shares will vest upon the commercial launch of the Company’s gene/gene product-based colon cancer test licensed from HDC or similar test based on mutual written agreement with the
Company. 
 40,000 of the Shares will vest upon the commercial launch of the Company’s gene/gene product-based pancreatic
cancer test licensed from HDC or similar test based on mutual written agreement with the Company. 
 20,000 of the Shares will
vest upon successful consummation of a sublicensing agreement with an instrument manufacturer to commercialize the cytogenetics automated image analysis technology licensed from HDC or similar product or test based on mutual written agreement with
the Company. 
 20,000 of the Shares will vest upon successful consummation of a sublicensing agreement with an instrument
manufacturer to commercialize the flow cytometry automated image analysis technology licensed from HDC or similar product or test based on mutual written agreement with the Company. 
 Notwithstanding the foregoing, in the event of a Change of Control (as defined below) of the Company in which the consideration payable to each common stockholder of the Company in connection with such
Change of Control has a Deemed Value (as defined below) of at least $4.00 per share (as adjusted for stock splits, stock dividends, reverse stock splits, and the like) then the Shares subject to the Warrant shall immediately vest in full.

 For purposes of this Agreement, “Change of Control” means either: 

(1) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without
limitation, any reorganization, merger or consolidation or stock transfer, but excluding any such transaction effected primarily for the purpose of changing the domicile of the Company), unless the Company’s stockholders of record immediately
prior to such transaction or series of related transactions hold, immediately after such transaction or series of related transactions, at least 50% of the voting power of the surviving or acquiring entity (provided that the sale by the Company of
its securities for the purposes of raising additional funds shall not constitute a Change of Control hereunder); or 
 (2) a
sale of all or substantially all of the assets of the Company. 

  
 5 








 For purposes of this Agreement, “Deemed Value” shall mean the value of consideration payable to
each common stockholder of the Company in connection with a Change of Control as determined in good faith by the Board. 
 In the event that the
Warrant Holder terminates the Medial Services Agreement with the Company at any time prior to the time when all Shares have vested pursuant to this Section 12, then the rights under this Agreement with respect to the unvested portion of the
Shares as of the date of termination shall immediately terminate. 
 13. Miscellaneous. 

13.1 Waivers and Amendments. This Agreement or any provisions hereof may be changed, waived, discharged or terminated only by a
statement in writing signed by the Company and by the Warrant Holder. 
 13.2 Governing Law. This Agreement shall be
governed by and construed and enforced in accordance with the laws of the State of Florida. 
 13.3 Notices. All notices
and other communications hereunder shall be in writing and shall be deemed to have been given when delivered by hand or by facsimile transmission, when telexed, or upon receipt when mailed by registered or certified mail (return receipt requested),
postage prepaid, to the parties at the following addresses (or at such other address for a party as shall be specified by like notice): 
  

	 	(i)	If to Company: 

 NeoGenomics,
Inc. 
 12701 Commonwealth Drive, Suite 5 
 Fort Myers, FL 33913 
  

			
	 Phone:
	  	(239) 768-0600
	 Attention:
	  	Chief Financial Officer
	 Facsimile:
	  	(239) 768-1672

  

	 	(ii)	If to Warrant Holder, the address listed in the preamble to this Agreement 

 13.4 Headings. The headings in this Agreement are for convenience of reference only, and shall not limit or otherwise affect the terms hereof. 

13.5 Closing of Books. The Company will at no time close its transfer books against the transfer of any Shares issued or issuable
upon the exercise of the Warrant in a manner that interferes with the timely exercise of the Warrant. 
 13.6 No Rights or
Liabilities as a Stockholder. This Agreement shall not entitle the Warrant Holder hereof to any voting rights or other rights as a stockholder of the Company with respect to the Shares prior to the exercise of the Warrant. No provision of this
Agreement, in the absence of affirmative action by the Warrant Holder to purchase the Shares, and no mere enumeration herein of the rights or privileges of the Warrant Holder, shall give rise to any liability of such Holder for the Exercise Price or
as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. 

  
 6 








 13.7 Successors. All the covenants and provisions of this Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns and transferees. 

13.8 Severability. If any provision of this Agreement shall be held to be invalid and unenforceable, such invalidity or
unenforceability shall not affect any other provision of this Agreement. 
 [SIGNATURE PAGE FOLLOWS] 

  
 7 








 IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed as of the date
first written above. 
  

			
	NEOGENOMICS, INC.
		
	By:	 	 /s/ Douglas M. VanOort

		 	Douglas M. VanOort
		 	Chairman and Chief Executive Officer
	
	WARRANT HOLDER
	
	 /s/ Maher Albitar, M.D

	Maher Albitar, M.D.



  
 8 








 EXHIBIT A 
 NOTICE OF EXERCISE 
 (To be signed only on exercise of Warrant) 

Dated:                     

 To: NeoGenomics, Inc. 
 The undersigned, pursuant to the provisions set forth in the attached Warrant Agreement, hereby irrevocably elects to: 
  ̈ purchase              shares of Common Stock covered by such Warrant Agreement and herewith
makes a cash payment of $            , representing the full purchase price for such shares at the price per share provided for in such Warrant Agreement. 

 ̈ purchase             
shares of Common Stock covered by such Warrant Agreement and herewith delivers              shares of Common Stock having a Market Price as of the last trading day preceding the date hereof
of $            , representing the full purchase price for such shares at the price per shares provided for in such Warrant Agreement. 

 ̈ acquire in a cashless exercise
             shares of Common Stock pursuant to the terms of Section 3.1 of such Warrant Agreement. 
 Please issue a certificate or certificates representing such shares of Common Stock in the name of the undersigned or in such other name as is specified below. 

 

			
	Signature:	 	  



 

			
	Name (print):	 	  



 

			
	Title (if applicable):	 	  



 

			
	Company (if applicable):	 	  



  
 1